OpenURL Connection Search

Select item for more details and to access through your institution.

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.
Published in:
Cancer & Metastasis Reviews, 2020, v. 39, n. 3, p. 999, doi. 10.1007/s10555-020-09876-9
By:
- Boonstra, Pieter A.;
- Wind, Thijs T.;
- van Kruchten, Michel;
- Schuuring, Ed;
- Hospers, Geke A. P.;
- van der Wekken, Anthonie J.;
- de Groot, Derk-Jan;
- Schröder, Carolien P.;
- Fehrmann, Rudolf S. N.;
- Reyners, Anna K. L.
Publication type:
Article
Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.
Published in:
JAMA Surgery, 2024, v. 159, n. 4, p. 429, doi. 10.1001/jamasurg.2023.7872
By:
- Mackay, Tara M.;
- Latenstein, Anouk E. J.;
- Augustinus, Simone;
- van der Geest, Lydia G.;
- Bogte, Auke;
- Bonsing, Bert A.;
- Cirkel, Geert A.;
- Hol, Lieke;
- Busch, Olivier R.;
- den Dulk, Marcel;
- van Driel, Lydi M. J.W.;
- Festen, Sebastiaan;
- de Groot, Derk-Jan A.;
- de Groot, Jan-Willem B.;
- Groot Koerkamp, Bas;
- Haj Mohammad, Nadia;
- Haver, Joyce T.;
- van der Harst, Erwin;
- de Hingh, Ignace H.;
- Homs, Marjolein Y. V.
Publication type:
Article
First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial.
Published in:
Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221077088
By:
- Levy, Sonja;
- Verbeek, Wieke H.M.;
- Eskens, Ferry A.L.M.;
- van den Berg, José G.;
- de Groot, Derk Jan A.;
- van Leerdam, Monique E.;
- Tesselaar, Margot E.T.
Publication type:
Article
Self‐Targeted Co‐Delivery of an Antibiotic and a Cancer‐Chemotherapeutic from Synthetic Liposomes for the Treatment of Infected Tumors.
Published in:
Advanced Functional Materials, 2023, v. 33, n. 32, p. 1, doi. 10.1002/adfm.202215153
By:
- Wang, Da‐Yuan;
- Cao, Yuanlong;
- Yang, Guang;
- Zhang, Siyu;
- van der Mei, Henny C.;
- Ren, Yijin;
- van Kooten, Theo G.;
- de Groot, Derk‐Jan A.;
- de Haan, Jacco J.;
- Shi, Linqi;
- Busscher, Henk J.
Publication type:
Article
Comparison of [18F]DOPA and [68Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy.
Published in:
European Journal of Hybrid Imaging, 2022, v. 6, n. 1, p. 1, doi. 10.1186/s41824-022-00133-6
By:
- Veenstra, Emile B.;
- Brouwers, Adrienne H.;
- de Groot, Derk Jan A.;
- Hofland, Johannes;
- Walenkamp, Annemiek M. E.;
- Brabander, Tessa;
- Zandee, Wouter T.;
- Noordzij, Walter
Publication type:
Article
Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations.
Published in:
Molecular Imaging & Biology, 2023, v. 25, n. 2, p. 435, doi. 10.1007/s11307-022-01775-5
By:
- van Sluis, Joyce;
- Noordzij, Walter;
- de Vries, Elisabeth G. E.;
- Kok, Iris C.;
- de Groot, Derk Jan A.;
- Jalving, Mathilde;
- Lub-de Hooge, Marjolijn N.;
- Brouwers, Adrienne H.;
- Boellaard, Ronald
Publication type:
Article
Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.
Published in:
Cancers, 2023, v. 15, n. 7, p. 2119, doi. 10.3390/cancers15072119
By:
- Woerdenbag, Herman J.;
- Olinga, Peter;
- Kok, Ellen A.;
- Brugman, Donald A. P.;
- van Ark, Ulrike F.;
- Ramcharan, Arwin S.;
- Lebbink, Paul W.;
- Hoogwater, Frederik J. H.;
- Knapen, Daan G.;
- de Groot, Derk Jan A.;
- Nijkamp, Maarten W.
Publication type:
Article
RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer.
Published in:
Molecular Oncology, 2019, v. 13, n. 11, p. 2361, doi. 10.1002/1878-0261.12550
By:
- Helden, Erik J.;
- Angus, Lindsay;
- Menke‐van der Houven van Oordt, C. Willemien;
- Heideman, Daniëlle A. M.;
- Boon, Eline;
- Es, Suzanne C.;
- Radema, Sandra A.;
- Herpen, Carla M. L.;
- Groot, Derk Jan A.;
- Vries, Elisabeth G. E.;
- Jansen, Maurice P. H. M.;
- Sleijfer, Stefan;
- Verheul, Henk M. W.
Publication type:
Article
Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
Published in:
Cancer Medicine, 2023, v. 12, n. 11, p. 12071, doi. 10.1002/cam4.5893
By:
- de Vries, Elisabeth G. E.;
- Rüschoff, Josef;
- Lolkema, Martijn;
- Tabernero, Josep;
- Gianni, Luca;
- Voest, Emile;
- de Groot, Derk Jan A.;
- Castellano, Daniel;
- Erb, Gilles;
- Naab, Julia;
- Donica, Margarita;
- Deurloo, Regula;
- van der Heijden, Michiel S.;
- Viale, Giuseppe
Publication type:
Article
Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice.
Published in:
Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.786191
By:
- Waaijer, Stijn J. H.;
- Suurs, Frans V.;
- Hau, Cheei-Sing;
- Vrijland, Kim;
- de Visser, Karin E.;
- de Groot, Derk Jan A.;
- de Vries, Elisabeth G. E.;
- Lub-de Hooge, Marjolijn N.;
- Schröder, Carolina P.
Publication type:
Article
Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
Published in:
Frontiers in Endocrinology, 2021, v. 11, p. N.PAG, doi. 10.3389/fendo.2021.627819
By:
- Dijkstra, Krijn K.;
- van den Berg, José G.;
- Weeber, Fleur;
- van de Haar, Joris;
- Velds, Arno;
- Kaing, Sovann;
- Peters, Dennis D. G. C.;
- Eskens, Ferry A. L. M.;
- de Groot, Derk-Jan A.;
- Tesselaar, Margot E. T.;
- Voest, Emile E.
Publication type:
Article
Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.
Published in:
Rheumatology, 2016, v. 55, n. 6, p. 1143, doi. 10.1093/rheumatology/kew063
By:
- van den Brom, Rob R. H.;
- Abdulahad, Wayel H.;
- Rutgers, Abraham;
- Kroesen, Bart-Jan;
- Roozendaal, Caroline;
- A. de Groot, Derk Jan;
- Schröder, Carolien P.;
- Hospers, Geke A. P.;
- Brouwer, Elisabeth
Publication type:
Article
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Published in:
International Journal of Cancer, 2006, v. 118, n. 8, p. 1892, doi. 10.1002/ijc.21580
By:
- Hougardy, Brigitte M.T.;
- Maduro, John H.;
- van der Zee, Ate G.J.;
- de Groot, Derk Jan A.;
- van den Heuvel, Fiona A.J.;
- de Vries, Elisabeth G.E.;
- de Jong, Steven
Publication type:
Article
89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 11, p. 1715, doi. 10.2967/jnumed.121.263079
By:
- Broer, Linda N.;
- Knapen, Daan G.;
- Suurs, Frans V.;
- Moen, Ingrid;
- Giesen, Danique;
- Waaijer, Stijn J. H.;
- Indrevoll, Baard;
- Ellingsen, Christine;
- Kristian, Alexander;
- Cuthbertson, Alan S.;
- de Groot, Derk-Jan A.;
- Cole, Patricia E.;
- de Vries, Elisabeth G. E.;
- Hagemann, Urs B.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
89Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263079
By:
- Broer, Linda N.;
- Knapen, Daan G.;
- Suurs, Frans Valentijn;
- Moen, Ingrid;
- Giesen, Danique;
- Waaijer, Stijn J. H.;
- Indrevoll, Baard;
- Ellingsen, Christine;
- Kristian, Alexander;
- Cuthbertson, Alan S.;
- de Groot, Derk-Jan A.;
- Cole, Patricia E.;
- de Vries, Elisabeth G. E.;
- Hagemann, Urs B.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263079
By:
- Broer, Linda N.;
- Knapen, Daan G.;
- Suurs, Frans V.;
- Moen, Ingrid;
- Giesen, Danique;
- Waaijer, Stijn J. H.;
- Indrevoll, Baard;
- Ellingsen, Christine;
- Kristian, Alexander;
- Cuthbertson, Alan S.;
- de Groot, Derk-Jan A.;
- Cole, Patricia E.;
- de Vries, Elisabeth G. E.;
- Hagemann, Urs B.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263079
By:
- Broer, Linda N.;
- Knapen, Daan G.;
- Suurs, Frans V.;
- Moen, Ingrid;
- Giesen, Danique;
- Waaijer, Stijn J. H.;
- Indrevoll, Baard;
- Ellingsen, Christine;
- Kristian, Alexander;
- Cuthbertson, Alan S.;
- de Groot, Derk-Jan A.;
- Cole, Patricia E.;
- de Vries, Elisabeth G. E.;
- Hagemann, Urs B.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
89Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263079
By:
- Broer, Linda N.;
- Knapen, Daan G.;
- Suurs, Frans V.;
- Moen, Ingrid;
- Giesen, Danique;
- Waaijer, Stijn J. H.;
- Indrevoll, Baard;
- Ellingsen, Christine;
- Kristian, Alexander;
- Cuthbertson, Alan S.;
- de Groot, Derk-Jan A.;
- Cole, Patricia E.;
- de Vries, Elisabeth G. E.;
- Hagemann, Urs B.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
89Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted 227Th-conjugate therapy in mice.
Published in:
Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263079
By:
- Broer, Linda N.;
- Knapen, Daan G.;
- Suurs, Frans V.;
- Moen, Ingrid;
- Giesen, Danique;
- Waaijer, Stijn J. H.;
- Indrevoll, Baard;
- Ellingsen, Christine;
- Kristian, Alexander;
- Cuthbertson, Alan S.;
- de Groot, Derk-Jan A.;
- Cole, Patricia E.;
- de Vries, Elisabeth G. E.;
- Hagemann, Urs B.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.259036
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Bailis, Julie M.;
- Stienen, Sabine;
- Friedrich, Matthias;
- Lee, Fei;
- van der Vegt, Bert;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.259036
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Bailis, Julie M.;
- Stienen, Sabine;
- Friedrich, Matthias;
- Lee, Fei;
- der Vegt, Bert van;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.259036
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Bailis, Julie M.;
- Stienen, Sabine;
- Friedrich, Matthias;
- Lee, Fei;
- van der Vegt, Bert;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.259036
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Bailis, Julie M.;
- Stienen, Sabine;
- Friedrich, Matthias;
- Fei Lee;
- van der Vegt, Bert;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.259036
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Bailis, Julie M.;
- Stienen, Sabine;
- Friedrich, Matthias;
- Fei Lee;
- van der Vegt, Bert;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.259036
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Bailis, Julie M.;
- Stienen, Sabine;
- Friedrich, Matthias;
- Lee, Fei;
- van der Vegt, Bert;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Published in:
Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.259036
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Bailis, Julie M.;
- Stienen, Sabine;
- Friedrich, Matthias;
- Lee, Fei;
- van der Vegt, Bert;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.241877
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Stienen, Sabine;
- Friedrich, Matthias;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Hooge, Marjolijn N. Lub-de
Publication type:
Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.241877
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Stienen, Sabine;
- Friedrich, Matthias;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.241877
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Stienen, Sabine;
- Friedrich, Matthias;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.24187
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Stienen, Sabine;
- Friedrich, Matthias;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.241877
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Stienen, Sabine;
- Friedrich, Matthias;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Hooge, Marjolijn N. Lub-de
Publication type:
Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.120.241877
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Stienen, Sabine;
- Friedrich, Matthias;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.
Published in:
Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.120.241877
By:
- Suurs, Frans V.;
- Lorenczewski, Grit;
- Stienen, Sabine;
- Friedrich, Matthias;
- de Vries, Elisabeth G. E.;
- de Groot, Derk Jan A.;
- Lub-de Hooge, Marjolijn N.
Publication type:
Article
Data-Driven Prioritization and Review of Targets for Molecular-Based Theranostic Approaches in Pancreatic Cancer.
Published in:
Journal of Nuclear Medicine, 2017, v. 58, n. 12, p. 1899, doi. 10.2967/jnumed.117.198440
By:
- Koller, Marjory;
- Hartmans, Elmire;
- de Groot, Derk Jan A.;
- Zhao, Xiao Juan;
- van Dam, Gooitzen M.;
- Nagengast, Wouter B.;
- Fehrmann, Rudolf S. N.
Publication type:
Article
Theranostics Using Antibodies and Antibody-Related Therapeutics.
Published in:
Journal of Nuclear Medicine, 2017, v. 58, p. 83S, doi. 10.2967/jnumed.116.186940
By:
- Moek, Kirsten L.;
- Giesen, Danique;
- Kok, Iris C.;
- de Groot, Derk Jan A.;
- Jalving, Mathilde;
- Fehrmann, Rudolf S. N.;
- Lub-de Hooge, Marjolijn N.;
- Brouwers, Adrienne H.;
- de Vries, Elisabeth G. E.
Publication type:
Article
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
Published in:
Oncologist, 2024, v. 29, n. 5, p. 431, doi. 10.1093/oncolo/oyad320
By:
- Spiekman, Ilse A C;
- Geurts, Birgit S;
- Zeverijn, Laurien J;
- Wit, Gijs F de;
- van der Noort, Vincent;
- Roepman, Paul;
- Leng, Wendy W J de;
- Jansen, Anne M L;
- Kusters, Benno;
- Beerepoot, Laurens V;
- Vos, Filip Y F L de;
- Groot, Derk-Jan A de;
- Groot, Jan Willem B de;
- Hoeben, Ann;
- Buter, Jan;
- Gelderblom, Hans A J;
- Voest, Emile E;
- Verheul, Henk M W
Publication type:
Article

Found: 36

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.

Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.

First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial.

Self‐Targeted Co‐Delivery of an Antibiotic and a Cancer‐Chemotherapeutic from Synthetic Liposomes for the Treatment of Infected Tumors.

Comparison of [<sup>18</sup>F]DOPA and [<sup>68</sup>Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy.

Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations.

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer.

Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice.

Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.

Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.

Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.

<sup>89</sup>Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted <sup>227</sup>Th-Conjugate Therapy in Mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging 1 reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

<sup>89</sup>Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup>Th-conjugate therapy in mice.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm.

Data-Driven Prioritization and Review of Targets for Molecular-Based Theranostic Approaches in Pancreatic Cancer.

Theranostics Using Antibodies and Antibody-Related Therapeutics.

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.